Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Open access

Published version of a preprint

Abstract

Purpose: PD-1/PD-L1 signaling promotes tumor growth while inhibiting effector cell–mediated antitumor immune responses. Here, we assessed the impact of single and dual blockade of PD-1/PD-L1, alone or in combination with lenalidomide, on accessory and immune cell function as well as multiple myeloma cell growth in the bone marrow (BM) milieu. Experimental Design: Surface expression of PD-1 on immune effector cells, and PD-L1 expression on CD138+ multiple myeloma cells and myeloid-derived suppressor cells (MDSC) were determined in BM from newly diagnosed (ND) multiple myeloma and relapsed/refractory (RR) multiple myeloma versus healthy donor (HD). We defined the impact of single and dual blockade of PD-1/PD-L1, alone and with lenalidomide, on autologous anti–multiple myeloma immune response and tumor cell growth. Results: Both ND and RR patient multiple myeloma cells have increased PD-L1 mRNA and surface expression compared with HD. There is also a significant increase in PD-1 expression on effector cells in multiple myeloma. Importantly, PD-1/PD-L1 blockade abrogates BM stromal cell (BMSC)-induced multiple myeloma growth, and combined blockade of PD-1/PD-L1 with lenalidomide further inhibits BMSC-induced tumor growth. These effects are associated with induction of intracellular expression of IFNγ and granzyme B in effector cells. Importantly, PD-L1 expression in multiple myeloma is higher on MDSC than on antigen-presenting cells, and PD-1/PD-L1 blockade inhibits MDSC-mediated multiple myeloma growth. Finally, lenalidomide with PD-1/PD-L1 blockade inhibits MDSC-mediated immune suppression. Conclusions: Our data therefore demonstrate that checkpoint signaling plays an important role in providing the tumor-promoting, immune-suppressive microenvironment in multiple myeloma, and that PD-1/PD-L1 blockade induces anti–multiple myeloma immune response that can be enhanced by lenalidomide, providing the framework for clinical evaluation of combination therapy. Clin Cancer Res; 21(20); 4607–18. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-0200

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 328

Metadata

Authors
Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., Kikuchi, S., Harada, T., Hideshima, T., Tai, Y.-T., Laubach, J. P., Raje, N., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., Munshi, N. C., Dorfman, D. M., Richardson, P. G., & Anderson, K. C.
Affiliations
  • Harvard University (US)
  • Massachusetts General Hospital (US)
  • Centre National de la Recherche Scientifique (FR)
  • 4Inserm UMR892, CNRS 6299, Université de Nantes, Nantes, France.
  • 6Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France.
  • Brigham and Women's Hospital (US)
Corresponding author
  • Görgün, Güllü
  • Anderson, Kenneth C.
Venue
Clinical Cancer Research
Published
2015-10-14
Volume
21
Issue
20
Pages
4607-4618
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1955732360
Cited by
309
References
53
Citations by year
2026: 11 · 2025: 13 · 2024: 17 · 2023: 21 · 2022: 26 · 2021: 35 · 2020: 41 · 2019: 25 · 2018: 45 · 2017: 41 · 2016: 28 · 2015: 6
FWCI
31.39
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion)
Funders
  • National Institutes of Health (5p01ca078378-15)
  • National Cancer Institute (R01CA166480, P01-CA-78378, R01- CA50947, P01-CA078378, P50CA100707, R01CA050947)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
lenalidomide, PD-1/PD-L1 blockade, multiple myeloma, immune checkpoint blockade, myeloid-derived suppressor cells, mesenchymal stem cells, tumor microenvironment, immunosuppression, interferon-gamma, granzyme B, combination immunotherapy, relapsed/refractory multiple myeloma
MeSH terms
Lenalidomide, Antibodies, Monoclonal, Antigen-Presenting Cells, Bone Marrow, Humans, Interferon-gamma, Multiple Myeloma, RNA, Messenger, Thalidomide, Signal Transduction, Cell Line, Tumor, Cell Proliferation, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0200
The paper
Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., Kikuchi, S., Harada, T., Hideshima, T., Tai, Y.-T., Laubach, J. P., Raje, N., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., . . . Anderson, K. C. (2015). Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.